New research suggests that adding an SGLT-2 inhibitor drug, dapagliflozin, to insulin therapy is helpful to patients with type 1 diabetes who are not able to maintain ideal blood glucose ranges with insulin alone. Because the drug can cause a slight increase in the kidney problem DKA, patients and their doctors should work closely together to monitor for any signs of DKA. Read more